Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab with add-on all-trans retinoic acid in relapsed/refractory multiple myeloma
NL-OMON46225Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab and tretinoin in multiple myeloma (MM) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Maximum tolerated dose, Recommended dose level and 1 more. Started Jul 2016; status: active, not recruiting.
02
Drugs
daratumumabtretinoin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON46225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46225.